Actively Recruiting

Phase 3
Age: 18Years +
All Genders
NCT07284901

Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

Led by Kailera · Updated on 2026-05-12

1700

Participants Needed

46

Research Sites

119 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The primary objective of this study is to demonstrate that KAI-9531 subcutaneous (SC) injection once weekly is superior to placebo on: * Percent change in body weight * Change in hemoglobin A1c (HbA1c)

CONDITIONS

Official Title

Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosed with type 2 diabetes mellitus (T2DM)
  • Receiving stable therapy for T2DM for at least 3 months before screening, including diet/exercise or oral medications except GLP-1R agonists, GLP-1R/GIPR dual agonists, or DPP-4 inhibitors
  • Body mass index (BMI) of 27 kg/m2 or higher
  • History of at least 1 unsuccessful attempt to lose weight with diet and exercise within the past 6 months
Not Eligible

You will not qualify if you...

  • Current or past diagnosis of type 1 diabetes mellitus or other diabetes types besides T2DM
  • History of diabetic ketoacidosis or hyperosmolar state/coma within 1 year before screening
  • History of severe hypoglycemia or hypoglycemia unawareness within 1 year before screening
  • Started medications causing significant weight gain within 3 months before screening, including tricyclic antidepressants, atypical antipsychotics, or mood stabilizers
  • Unstable weight with more than 5% change within 3 months before screening
  • Family or personal history of multiple endocrine neoplasia Type 2 or medullary thyroid cancer
  • Uncontrolled hypertension or unstable cardiovascular disease
  • History of chronic or acute pancreatitis
  • Known significant gastric emptying abnormality or chronic use of medications affecting gastrointestinal motility for more than 30 days within 3 months before screening
  • History of suicide attempt
  • History of active or unstable major depressive disorder or other severe psychiatric disorder within 2 years before screening
  • Received treatment with semaglutide, tirzepatide, GLP-1 receptor agonists, GLP-1/GIP agonists, glucagon receptor agonists, or other weight loss medications or treatments besides diet and exercise within 3 months before screening

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 46 locations

1

Kailera Clinical Site

Cullman, Alabama, United States, 35055

Actively Recruiting

2

Kailera Clinical Site

Phoenix, Arizona, United States, 85012

Actively Recruiting

3

Kailera Clinical Site

Sun City, Arizona, United States, 85351

Actively Recruiting

4

Kailera Clinical Site

Little Rock, Arkansas, United States, 72205

Actively Recruiting

5

Kailera Clinical Site

Escondido, California, United States, 92025

Actively Recruiting

6

Kailera Clinical Site

Northridge, California, United States, 91325

Actively Recruiting

7

Kailera Clinical Site

Oceanside, California, United States, 92058

Actively Recruiting

8

Kailera Clinical Site

Toluca Lake, California, United States, 91602

Actively Recruiting

9

Kailera Clinical Site

Stamford, Connecticut, United States, 06905

Actively Recruiting

10

Kailera Clinical Site

Jupiter, Florida, United States, 33458

Actively Recruiting

11

Kailera Clinical Site

Orange City, Florida, United States, 32763

Actively Recruiting

12

Kailera Clinical Site

Lilburn, Georgia, United States, 30047

Actively Recruiting

13

Kailera Clinical Site

Springfield, Illinois, United States, 62702

Actively Recruiting

14

Kailera Clinical Site

Newton, Kansas, United States, 67114

Actively Recruiting

15

Kailera Clinical Site

Shreveport, Louisiana, United States, 71105

Actively Recruiting

16

Kailera Clinical Site

Columbia, Maryland, United States, 21045

Actively Recruiting

17

Kailera Clinical Site

Missoula, Montana, United States, 59804

Actively Recruiting

18

Kailera Clinical Site

Lincoln, Nebraska, United States, 68516

Actively Recruiting

19

Kailera Clinical Site

Las Vegas, Nevada, United States, 89148

Actively Recruiting

20

Kailera Clinical Site

Albany, New York, United States, 12203

Actively Recruiting

21

Kailera Clinical Site

Greensboro, North Carolina, United States, 27405

Actively Recruiting

22

Kailera Clinical Site

Morehead City, North Carolina, United States, 28557

Actively Recruiting

23

Kailera Clinical Site

Chickasha, Oklahoma, United States, 73018

Actively Recruiting

24

Kailera Clinical Site

Spartanburg, South Carolina, United States, 29303

Actively Recruiting

25

Kailera Clinical Site

Chattanooga, Tennessee, United States, 37405

Active, Not Recruiting

26

Kailera Clinical Site

Amarillo, Texas, United States, 79124

Actively Recruiting

27

Kailera Clinical Site

Brownsville, Texas, United States, 78526

Actively Recruiting

28

Kailera Clinical Site

DeSoto, Texas, United States, 75115

Actively Recruiting

29

Kailera Clinical Site

Tomball, Texas, United States, 77375

Actively Recruiting

30

Kailera Clinical Site

Salt Lake City, Utah, United States, 84117

Actively Recruiting

31

Kailera Clinical Site

Richmond, Virginia, United States, 23236

Actively Recruiting

32

Kailera Clinical Site

Bruce, Australian Capital Territory, Australia, 2617

Actively Recruiting

33

Kailera Clinical Site

Blacktown, New South Wales, Australia, 2148

Actively Recruiting

34

Kailera Clinical Site

Kanwal, New South Wales, Australia, 2259

Actively Recruiting

35

Kailera Clinical Site

Sydney, New South Wales, Australia, 2100

Actively Recruiting

36

Kailera Clinical Site

Sydney, New South Wales, Australia, 2228

Actively Recruiting

37

Kailera Clinical Site

Wollongong, New South Wales, Australia, 2500

Actively Recruiting

38

Kailera Clinical Site

Camberwell, Victoria, Australia, 3124

Actively Recruiting

39

Kailera Clinical Site

Melbourne, Victoria, Australia, 3025

Actively Recruiting

40

Kailera Clinical Site

Grafton, Auckland, New Zealand, 1010

Actively Recruiting

41

Kailera Clinical Site

New Lynn, Auckland, New Zealand, 0610

Actively Recruiting

42

Kailera Clinical Site

Silverdale, Auckland, New Zealand, 0932

Actively Recruiting

43

Kailera Clinical Site

Takapuna, Auckland, New Zealand, 0622

Actively Recruiting

44

Kailera Clinical Site

Nawton, Hamilton, New Zealand, 3200

Actively Recruiting

45

Kailera Clinical Site

Hastings, New Zealand, 4120

Actively Recruiting

46

Kailera Clinical Site

Nelson, New Zealand, 7011

Actively Recruiting

Loading map...

Research Team

K

Kailera Therapeutics, Inc.

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

5

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here